
    
      This is a single arm Phase I study with multiple dosing cohorts as noted below:

        -  Schedule A: MLN7243 1 mg

        -  Schedule A: MLN7243 2 mg

        -  Schedule A: MLN7243 4 mg

        -  Schedule A: MLN7243 8 mg

        -  Schedule A: MLN7243 12 mg

        -  Schedule A: MLN7243 18 mg

        -  Schedule A: MLN7243 Homozygous Mutant 4 mg
    
  